Sequence variants in cell cycle control pathway, x-ray exposure, and lung cancer risk: A multicenter case-control study in Central Europe

Cancer Research

Volumn 66, Issue 16, 2006, Pages 8280-8286

  Hung, Rayjean J ^a   Boffetta, Paolo ^a   Canzian, Federico ^a   Moullan, Norman ^a   Szeszenia Dabrowska, Neonila ^b   Zaridze, David ^c   Lissowska, Jolanta ^d   Rudnai, Peter ^e   Fabianova, Eleonora ^f   Mates, Dana ^g   Foretova, Lenka ^h   Janout, Vladimir ⁱ   Bencko, Vladimir ^j   Chabrier, Amelie ^a   Landi, Stefano ^k   Gemignani, Federica ^a   Hall, Janet ^a   Brennan, Paul ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b NOFER INSTITUTE OF OCCUPATIONAL MEDICINE   (Poland)

^c N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^d INSTITUTE OF ONCOLOGY   (Poland)

^e Jozsef Fodor National Center for Public Health   (Hungary)

^f Specialized Institute of Hygiene and Epidemiology   (Slovakia)

^g NATIONAL INSTITUTE OF PUBLIC HEALTH   (Romania)

^h MASARYK MEMORIAL CANCER INSTITUTE   (Czech Republic)

ⁱ PALACKÝ UNIVERSITY   (Czech Republic)

^j CHARLES UNIVERSITY   (Czech Republic)

^k UNIVERSITY OF PISA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ARGININE; PROLINE; PROTEIN CCND1; PROTEIN CDKN2A; PROTEIN P53; THREONINE; UNCLASSIFIED DRUG;

ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CELL CYCLE REGULATION; CONTROLLED STUDY; DNA DAMAGE; DNA MODIFICATION; EUROPE; GENE REPLICATION; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTRON; LUNG CANCER; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RADIATION DOSE; RADIATION EXPOSURE; X RAY;

EID: 33748036709     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-3099     Document Type: Article

References (45)

1. International Agency of Research on Cancer. Tobacco smoke and involuntary smoking. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. Lyon: IARC; 2004. p. 1-1382.
2. Krokan HE, Nilsen H, Skorpen F, Otterlei M, Slupphaug G. Base excision repair of DNA in mammalian cells. FEBS Lett 2000;476:73-7.
3. International Agency of Research on Cancer. Ionizing radiation, Part 1: X- and -y-radiation, and neutrons. IARC monographs on the evaluation of the carcinogenic risk of chemicals to humans. Lyon: IARC; 2000. p. 1-448.
4. Wakeford R. The cancer epidemiology of radiation. Oncogene 2004;23:6404-28.
5. Boffetta P, Trichopoulos D. Cancer of the lung, larynx, and pleura In: Adami HO, Hunter D, Trichopoulos D, editors. Text book of cancer epidemiology. New York Oxford University Press; 2002. pp. 248-80.
6. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001;411:366-74.
7. Fei P, El Deiry WS. P53 and radiation responses. Oncogene 2003;22:5774-83.
8. Teich NM. Oncogenes and cancer. In: Franks LM, Teich NM, editors. Introduction to the cellular and molecular biology of cancer. New York: Oxford University Press; 1998. pp. 169-201.
9. Sherr CJ. Cancer cell cycles. Science 1996;274:1672-7.
10. Shintani S, Mihara M, Ueyama Y, Matsumura T, Wong DT. Cyclin D1 overexpression associates with radiosensitivity in oral squamous cell carcinoma. Int J Cancer 2001;96:159-65.
11. Coco Martin JM, Balkenende A, Verschoor T, Lallemand F, Michalides R. Cyclin D1 overexpression enhances radiation-induced apoptosis and radiosensitivity in a breast tumor cell line. Cancer Res 1999;59:1134-40.
12. Ju GZ, Wang XM, Fu SB, Liu SZ. Effect of ionizing radiation on the expression of p16, cyclinD1, and CDK4 in mouse thymocytes and splenocytes. Biomed Environ Sci 2003;16:47-52.
13. Cuddihy AR, Bristow RG. The p53 protein family and radiation sensitivity: yes or no? Cancer Metastasis Rev 2004;23:237-57.
14. Enns L, Bogen KT, Wizniak J, Murtha AD, Weinfeld M. Low-dose radiation hypersensitivity is associated with p53-dependent apoptosis. Mol Cancer Res 2004;2:557-66.
15. Criswell T, Leskov K, Miyamoto S, Luo G, Boothman DA, Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. Oncogene 2003;22:5813-27.
16. Cordon-Cardo C. Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am J Pathol 1995;147:545-60.
17. Liggett WH, Jr., Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 1998;16:1197-206.
18. Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J. Alternate splicing produces a novel cyclin Dl transcript. Oncogene 1995;11:1005-11.
19. Solomon DA, Wang Y, Fox SR, et al. Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem 2003;278:30339-47.
20. Kong S, Amos CI, Luthra R, Lynch PM, Levin B, Frazier ML. Effects of cyclin D1 polymorphism on age of onset of hereditary nonpolyposis colorectal cancer. Cancer Res 2000;60:249-52.
21. Lu F, Gladden AB, Diehl JA. An alternatively spliced cyclin Dl isoform, cyclin D1b, is a nuclear oncogene. Cancer Res 2003;63:7056-61.
22. Qiuling S, Yuxin Z, Suhua Z, Cheng X, Shuguang L, Fengsheng H. Cyclin D1 gene polymorphism and susceptibility to lung cancer in a Chinese population. Carcinogenesis 2003;24:1499-503.
23. Thomas M, Kalita A, Labrecque S, Pim D, Banks L, Matlashewski G. Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol 1999;19:1092-100.
24. Dumont P, Leu JI, Della PA III, George DL, Murphy M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 2003;33:357-65.
25. Matakidou A, Eisen T, Houlston RS. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 2003;18:377-85.
26. Lazar V, Hazard F, Bertin F, Janin N, Bellet D, Bressac B. Simple sequence repeat polymorphism within the p53 gene. Oncogene 1993;8:1703-5.
27. Wu X, Zhao H, Amos CI, et al. p53 Genotypes and haplotypes associated with lung cancer susceptibility and ethnicity. J Natl Cancer Inst 2002;94:681-90.
28. Landi S, Gemignani F, Gioia-Patricola L, Chabrier A, Canzian F. Evaluation of a microarray for genotyping polymorphisms related to xenobiotic metabolism and DNA repair. Biotechniques 2003;35:816-7.
29. Gorgoulis VG, Zacharatos P, Kotsinas A, et al. Alterations of the p16-pRb pathway and the chromosome locus 9p21-22 in non-small-cell lung carcinomas: relationship with p53 and MDM2 protein expression. Am J Pathol 1998;153:1749-65.
30. Kim DH, Nelson HH, Wiencke JK, et al. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 2001;61:3419-24.
31. Ng PC, Henikoff S. Accounting for human polymorphisms predicted to affect protein function. Genome Res 2002;12:436-46.
32. Boffetta P, Mannetje A, Zaridze D, et al. Occupational X-ray examinations and lung cancer risk. Int J Cancer 2003;115:263-7.
33. Hung RJ, Brennan P, Canzian F, et al. Large-scale investigation of base excision repair genetic polymorphisms and lung cancer risk in a multicenter study. J Natl Cancer Inst 2005;97:567-76.
34. Morin PA, Saiz R, Monjazeb A. High-throughput single nucleotide polymorphism genotyping by fluorescent 5′ exonuclease assay. Biotechniques 1999;27:538-50.
35. Excoffier L, Slatkin M. Maximum-likelihood estimation of molecular haplotype frequencies in a diploid population. Mol Biol Evol 1995;12:921-7.
36. Mander AP. Haplotype analysis in population-based association studies. The Stata Journal 2001;1:58-75.
37. Thompson D, Witte JS, Slattery M, Goldgar D. Increased power for case-control studies of single nucleotide polymorphisms through incorporation of family history and genetic constraints. Genet Epidemiol 2004;27:215-24.
38. Wacholder S, Chanock S, Garcia-Closas M, El Ghormli L, Rothman N. Assessing the probability that a positive report is false: an approach for molecular epidemiology studies. J Natl Cancer Inst 2004;96:434-42.
39. Lozano G, Levine AJ. Tissue-specific expression of p53 in transgenic mice is regulated by intron sequences. Mol Carcinog 1991;4:3-9.
40. Beenken SW, Karsenty G, Raycroft L, Lozano G. An intron binding protein is required for transformation ability of p53. Nucleic Acids Res 1991;19:4747-52.
41. Gemignani F, Moreno V, Landi S, et al. A TP53 polymorphism is associated with increased risk of colorectal cancer and with reduced levels of TP53 mRNA. Oncogene 2004;23:1954-6.
42. Hinata N, Shirakawa T, Zhang Z, et al. Radiation induces p53-dependent cell apoptosis in bladder cancer cells with wild-type-p53 but not in p53-mutated bladder cancer cells. Urol Res 2003;31:387-96.
43. Rossner P, Jr., Chvatalova I, Schmuczerova J, Milcova A, Rossner P, Sram RJ. Comparison of p53 levels in lymphocytes and in blood plasma of nuclear power plant workers. Mutat Res 2004;556:55-63.
44. 1 arrest is not defective in fibroblasts from Li-Fraumeni families without TP53 mutations. Br J Cancer 1999;79:1657-64.
45. Yoo SS, Carter D, Turner BC, et al. Prognostic significance of cyclin D1 protein levels in early-stage larynx cancer treated with primary radiation. Int J Cancer 2000;90:22-8.